Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10133363 | 0.85 | NPY5R (0.46) | KDM4EHTTATMALDH1A1NPC1 | |
| SCHEMBL13203779 | 0.85 | NPY5R (0.46) | KDM4EHTTATMALDH1A1NPC1 | |
| SCHEMBL13565823 | 0.82 | PTGER4 (0.37) | KDM4E | |
| SCHEMBL13973373 | 0.79 | KDM4E (0.46) | KDM4EHTTATMALDH1A1NPC1 | |
| SCHEMBL10133356 | 0.79 | BRD4 (0.42) | ALDH1A1NPC1RAB9ABRD4GRIA2 | |
| SCHEMBL12882308 | 0.78 | BRD4 (0.36) | ALDH1A1BRD4GRIA2 | |
| SCHEMBL13052680 | 0.78 | KDM4E (0.42) | KDM4EHTTATMALDH1A1NPC1 | |
| SCHEMBL13204283 | 0.73 | HTT (0.58) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10114008 | 0.73 | HTT (0.58) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10113981 | 0.72 | RAB9A (0.61) | HTTALDH1A1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | KDM4E 1668/4885HTT 2081/4885ATM 4841/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | KDM4E 1627/4885HTT 1904/4885ATM 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.